Tumor-associated antigen and alpha-gal epitope on vaccine cell surface (None established (TAA + α-gal is sometimes used in experimental protocols, but there is no widely accepted abbreviation))

Tumor-associated antigens and alpha-gal epitopes on vaccine cell surface is not a single, canonical protein or receptor but a composite concept widely used in cancer vaccine and immunotherapy research. Tumor-associated antigens (TAAs) are a broad class of proteins or glycoproteins preferentially expressed by, or uniquely found on, cancer cells. The alpha-gal epitope (Galα1-3Galβ1-4GlcNAc-R) is a carbohydrate motif not normally synthesized by humans but present in most mammals; humans have abundant anti-Gal antibodies. When tumor cells, cell membranes, or lysates are engineered to express α-gal epitopes and used as a vaccine, anti-Gal antibodies bind to the α-gal epitope, directing the vaccine material for rapid uptake by antigen-presenting cells (APCs) through Fcγ receptor interaction. This process increases the immune system's exposure to tumor antigens and can elicit a stronger anti-tumor immune response, as demonstrated in preclinical and experimental models, particularly in cancers like pancreatic cancer and melanoma[1][2][3][5][7]. Similar approaches are proposed for infectious disease vaccines. However, this "target" is not a traditional receptor or molecule and thus is considered an engineered composite rather than a canonical therapeutic target.

Other names

Tumor-associated antigens (TAAs)alpha-gal epitope (α-gal)Galα1-3Galβ1-4GlcNAc-Ranti-Gal targetα-Gal antigen

Engineered tumor cell or viral vaccine surface antigens are glycoengineered to express α-gal epitopes. Upon vaccination, natural anti-Gal antibodies in the recipient bind to α-gal epitopes, forming immune complexes. These immune complexes interact via their Fc domain with Fcγ receptors on APCs, facilitating enhanced uptake, processing, and presentation of tumor (or viral) antigens, leading to stronger T-cell and B-cell mediated immunity against the disease-associated antigens[1][2][3][4][5][6].